GlassScriptPhysician profile
Ji Can Yang
NPI 1093004012
$1,228.22
in general payments reported to CMS, 2019-2025
12 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2021: $19.70 · 2022: $109 · 2023: $214 · 2024: $181 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.90 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $281.33 | 2019-2023 | Mitraclip |
| Edwards Lifesciences Corporation | $214.99 | 2025 | Evoque |
| Actelion Pharmaceuticals US, INC. | $140.60 | 2023-2025 | Uptravi, Opsumit |
| Heartflow, INC. | $130.03 | 2025 | |
| Boston Scientific Corporation | $116.38 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $112.98 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.51 | 2022 | |
| Baxter Healthcare | $46.36 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $44.76 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Novo Nordisk INC | $20.06 | 2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ji Can Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.